19 Jun 2019 07:00
Â
19 June 2019
 Avacta Group plc
("Avacta", the "Company" or the "Group")
Â
Turner Pope Investor Evening
Â
Avacta Group plc (AIM: AVCT.L), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that the Group's Chief Executive, Alastair Smith, will be presenting at an investor evening hosted by Turner Pope Investments on Wednesday, 3 July 2019. The event will be held in London, EC2 and commence at 4pm.
Â
To register your interest, please email info@turnerpope.com or call on 0203 621 4124.
Â
- Ends -
Â
Â
Â
For further information from Avacta Group plc, please contact:
Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer  | Tel: +44 (0) 844 414 0452 www.avacta.com |
finnCap Ltd (Nominated Adviser and Joint Broker) Geoff Nash / Giles Rolls - Corporate Finance Tim Redfern - ECM  WG Partners (Joint Broker) Nigel Birks / Nigel Barnes David Wilson / Claes Spang  | Tel: +44 (0) 207 220 0500 www.finncap.com   Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9217 www.wgpartners.co.uk  |
Turner Pope Investments James Pope / Ben Turner  Yellow Jersey PR (Financial Media and IR) Sarah Hollins Harriet Jackson  Zyme Communications (Trade and Regional Media) Katie Odgaard | Tel: +44 (0) 203 621 4120 www.turnerpope.com   Tel: +44 (0)7764 947 137 Tel: +44 (0)7544 275 882 avacta@yellowjerseypr.com  Tel: +44 (0)7787 502 947 katie.odgaard@zymecommunications.com  |
About Avacta Group plc - https://www.avacta.com
Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Â
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Â
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
Â
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts